Cognition Therapeutics to Report Second Quarter 2024 Financial Results
Cognition Therapeutics (Nasdaq: CGTX), a clinical-stage biopharmaceutical company, has announced it will release its Q2 2024 financial results on August 8, 2024, before market open. The company will host a conference call and live audio webcast at 8:30 a.m. ET on the same day to discuss the results and provide a business update.
Cognition Therapeutics focuses on developing treatments for neurodegenerative disorders. Their lead candidate, CT1812, is being investigated for Alzheimer's disease, dementia with Lewy bodies (DLB), and dry age-related macular degeneration (dry AMD). The company believes CT1812 and its pipeline of σ-2 receptor modulators can regulate impaired pathways in these diseases, offering a potentially distinct approach from other treatments in development.
Cognition Therapeutics (Nasdaq: CGTX), un'azienda biofarmaceutica in fase clinica, ha annunciato che pubblicherà i suoi risultati finanziari del secondo trimestre 2024 il 8 agosto 2024, prima dell'apertura del mercato. L'azienda organizzerà una conferenza telefonica e una trasmissione audio in diretta alle 8:30 ET dello stesso giorno per discutere i risultati e fornire un aggiornamento aziendale.
Cognition Therapeutics si concentra sullo sviluppo di trattamenti per i disturbi neurodegenerativi. Il loro candidato principale, CT1812, è attualmente in fase di studio per la malattia di Alzheimer, la demenza con corpi di Lewy (DLB) e la degenerazione maculare legata all'età secca (dry AMD). L'azienda ritiene che CT1812 e il suo portfolio di modulatori del recettore σ-2 possano regolare i percorsi compromessi in queste malattie, offrendo un approccio potenzialmente distintivo rispetto ad altri trattamenti in fase di sviluppo.
Cognition Therapeutics (Nasdaq: CGTX), una empresa biofarmacéutica en etapa clínica, ha anunciado que publicará sus resultados financieros del segundo trimestre de 2024 el 8 de agosto de 2024, antes de la apertura del mercado. La empresa llevará a cabo una conferencia telefónica y una transmisión de audio en vivo a las 8:30 a.m. ET el mismo día para discutir los resultados y proporcionar una actualización empresarial.
Cognition Therapeutics se centra en desarrollar tratamientos para trastornos neurodegenerativos. Su candidato principal, CT1812, está siendo investigado para la enfermedad de Alzheimer, la demencia con cuerpos de Lewy (DLB) y la degeneración macular relacionada con la edad seca (dry AMD). La empresa cree que CT1812 y su cartera de moduladores del receptor σ-2 pueden regular las vías deterioradas en estas enfermedades, ofreciendo un enfoque potencialmente distinto al de otros tratamientos en desarrollo.
Cognition Therapeutics (Nasdaq: CGTX)는 임상 단계의 생명공학 회사로서 2024년 2분기 재무 결과를 2024년 8월 8일에 시장 개장 전 발표할 것이라고 발표했습니다. 이날 오전 8:30 ET에 결과를 논의하고 비즈니스 업데이트를 제공하기 위해 전화 회의 및 생방송 오디오 웨비나를 개최할 예정입니다.
Cognition Therapeutics는 신경퇴행성 질환 치료제 개발에 중점을 두고 있습니다. 그들의 주요 후보인 CT1812는 알츠하이머병, 루이소체치매(DLB), 건성 노인성 황반변성(dry AMD)에 대해 연구되고 있습니다. 회사는 CT1812와 σ-2 수용체 조절제 파이프라인이 이러한 질병의 손상된 경로를 조절할 수 있다고 믿고 있으며, 이는 다른 개발 중인 치료제와는 차별화된 접근 방식을 제공할 것입니다.
Cognition Therapeutics (Nasdaq: CGTX), une entreprise biopharmaceutique en phase clinique, a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 le 8 août 2024, avant l'ouverture du marché. L'entreprise tiendra une conférence téléphonique et une diffusion audio en direct à 8h30 ET le même jour pour discuter des résultats et fournir une mise à jour de l'entreprise.
Cognition Therapeutics se concentre sur le développement de traitements pour les troubles neurodégénératifs. Leur principal candidat, CT1812, est en cours d'étude pour la maladie d'Alzheimer, la démence à corps de Lewy (DLB) et la dégénérescence maculaire liée à l'âge sèche (dry AMD). L'entreprise croit que CT1812 et son pipeline de modulateurs de récepteurs σ-2 peuvent réguler des voies altérées dans ces maladies, offrant ainsi une approche potentiellement distincte par rapport à d'autres traitements en développement.
Cognition Therapeutics (Nasdaq: CGTX), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat angekündigt, dass es seine Finanzergebnisse für das zweite Quartal 2024 am 8. August 2024 vor Markteröffnung veröffentlichen wird. Das Unternehmen wird am selben Tag um 8:30 Uhr ET eine Konferenzschaltung und eine Live-Audiowiedergabe abhalten, um die Ergebnisse zu erörtern und ein Unternehmensupdate zu geben.
Cognition Therapeutics konzentriert sich auf die Entwicklung von Behandlungen für neurodegenerative Erkrankungen. Ihr Hauptkandidat, CT1812, wird für Alzheimer-Krankheit, Lewy-Körper-Demenz (DLB) und trockene altersbedingte Makuladegeneration (dry AMD) untersucht. Das Unternehmen ist der Ansicht, dass CT1812 und sein Portfolio an σ-2-Rezeptormodulatoren die beeinträchtigten Wege bei diesen Krankheiten regulieren können und somit einen potenziell unterschiedlichen Ansatz im Vergleich zu anderen in der Entwicklung befindlichen Behandlungen bieten.
- Cognition Therapeutics is advancing clinical programs for multiple neurodegenerative disorders
- The company's lead candidate CT1812 targets multiple indications including Alzheimer's disease and dry AMD
- Cognition's σ-2 receptor modulator approach may offer a unique mechanism compared to other treatments in development
- None.
- Conference Call and Live Audio Webcast Scheduled for August 8, 2024 -
PURCHASE, NY.., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), today announced that the Company will release financial results for the second quarter ended June 30, 2024 on Thursday August 8, 2024 before the market opens. Following the release, management will host a conference call at 8:30 a.m. ET on the same day to review the financial and operating results and provide a business update.
| Conference Call | |
| Date / Time | August 8, 2024 at 8:30am ET / 5:30am PT |
Telephone Access: | US/Canada Participant Toll-Free Dial-in Number: (800) 715-9871 US/Canada Participant International Dial-In Number: (646) 307-1963 Conference ID Number: 3702003 |
Webcast Access: | The audio webcast with live Q&A will be accessible at https://edge.media-server.com/mmc/p/3napeebe or via the Investor Relations section of Cognition’s website. An archive of the webcast and presentation will be available for 90 days beginning at approximately 10:30 a.m. ET on August 8, 2024. |
About Cognition Therapeutics:
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases. We believe that targeting the σ-2 receptor with CT1812 represents a mechanism functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. More about Cognition Therapeutics and its pipeline can be found at https://cogrx.com/.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data and pre-clinical studies being predictive of the results of clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; changes in applicable laws or regulations; the possibility that the we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; the impacts of ongoing global and regional conflicts; the impact of the COVID-19 pandemic on our business, supply chain and labor force; and the risks and uncertainties described in the “Risk Factors” section of our annual and quarterly reports filed the Securities & Exchange Commission. These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
| Contact Information: Cognition Therapeutics, Inc. info@cogrx.com | Casey McDonald (media) Tiberend Strategic Advisors, Inc. cmcdonald@tiberend.com | Mike Moyer (investors) LifeSci Advisors mmoyer@lifesciadvisors.com |
FAQ
When will Cognition Therapeutics (CGTX) release its Q2 2024 financial results?
What time is Cognition Therapeutics' (CGTX) Q2 2024 earnings call scheduled for?
What is Cognition Therapeutics' (CGTX) lead drug candidate and what conditions does it target?
How does Cognition Therapeutics' (CGTX) approach to treating neurodegenerative disorders differ from others?
